Clinical trials: Pheochromocytomas
Pheochromocytomas, Paragangliomas
Italian Multicenter Experience With Radioreceptor-assisted Therapy (PRRT)
This multicenter retrospective Italian study evaluates the efficacy and safety of PRRT in patients with advanced, unresectable or metastatic pheochromocytomas and paragangliomas (PPGL).
- Trial name
- PRRT-PGL-PHEO (NCT07538791)
- Testing
- Peptide Receptor Radionuclide Therapy (PRRT)
- Where
- 10 sites in Italy
- Volunteers
- 210 people
- Sponsor
- Azienda USL Reggio Emilia - IRCCS
Pheochromocytoma, Paraganglioma
Content Validation of Quality of Life and Symptom Questionnaires for Pheochromocytoma and Paraganglioma
The purpose of this qualitative study is to evaluate the clarity and comprehensiveness of two disease-specific questionnaires, and to evaluate how effective these questionnaires are at assessing the quality of life and symptoms…
- Trial name
- NCT00911729
- Where
- United States
- Volunteers
- 24 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Pheochromocytoma, Paraganglioma
Phase 1 Study of Iobenguane (MIBG) I 131 in Patients With Malignant Pheochromocytoma/Paraganglioma
The purpose of this study is to determine whether iobenguane I 131 is safe and effective in patients with malignant pheochromocytoma or paraganglioma.
- Trial name
- NCT00458952
- Testing
- Ultratrace Iobenguane (MIBG) I 131
- Where
- 3 sites in United States
- Volunteers
- 24 people
- Sponsor
- Molecular Insight Pharmaceuticals, Inc.
Neoplasm Metastasis, Thyroid Neoplasm
Cryoablation of Bone Metastases From Endocrine Tumors
This study will evaluate the clinical response and safety of cone beam computed-tomography guided percutaneous cryoablation in bone metastases from thyroid, adrenal and neuroendocrine tumors in 30 patients.
- Conditions
- Neoplasm Metastasis, Thyroid Neoplasm, Pheochromocytoma, Adrenal Neoplasm
- Trial name
- NCT03986593
- Testing
- cryoablation
- Where
- Brazil
- Volunteers
- 17 people
- Sponsor
- Instituto do Cancer do Estado de São Paulo
Medullary Thyroid Cancer
Natural History Study of Children and Adults With Medullary Thyroid Cancer
Background: Medullary thyroid cancer (MTC) is a rare cancer of the thyroid gland. In children and adults, it is often part of a condition called Multiple Endocrine Neoplasia 2 (MEN2).
- Trial name
- NCT01660984
- Where
- United States
- Volunteers
- 105 people
- Sponsor
- National Cancer Institute (NCI)
Phaeochromocytoma, Paraganglioma
Phase I Trial of Vandetanib Combined With 131I-mIBG to Treat Patients With Advanced Phaeochromocytoma and Paraganglioma
The phase I trial aims to determine the recommended phase II dose (RP2D) of vandetanib in combination with standard radiation therapy, 131I-mIBG, in patients with advanced phaeochromocytoma (phaeo) and paraganglioma (PG) by…
- Trial name
- VIBRaNT (NCT01941849)
- Testing
- Vandetanib, 131I-mIBG
- Where
- 3 sites in United Kingdom
- Sponsor
- University College, London
Phaeochromocytoma Crisis, Hemodynamic Instability
Magnesium and Dexmedetomidine in Pheochromocytoma
Anesthesia management of pheochromocytoma excision surgery is associated with severe hemodynamic fluctuations.The objective of this study was to compare the hypertensive episodes requiring sodium nitroprusside administration…
- Trial name
- NCT05102058
- Testing
- Magnesium-Dexmedetomidine
- Volunteers
- 108 people
- Sponsor
- Istanbul University
Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma
Testing the Addition of an Anticancer Drug, Olaparib, to the Usual Chemotherapy (Temozolomide) for Advanced Neuroendocrine Cancer
This phase II trial studies how well the addition of olaparib to the usual treatment, temozolomide, works in treating patients with neuroendocrine cancer (pheochromocytoma or paraganglioma) that has spread from where it first…
- Conditions
- Advanced Adrenal Gland Pheochromocytoma, Advanced Paraganglioma, Metastatic Adrenal Gland Pheochromocytoma, Metastatic Paraganglioma
- Trial name
- NCT04394858
- Testing
- Biospecimen Collection, Computed Tomography with Contrast, Magnetic Resonance Imaging
- Where
- 163 sites in United States
- Volunteers
- 46 people
- Sponsor
- National Cancer Institute (NCI)
Pheochromocytoma, Paraganglioma
Infrared Thermography Associated With Cutaneous Microcirculation for Detection of Brown-adipose Tissue (MICROBAT)
Patients affected by pheochromocytoma (PHEO) have brown-adipose tissue (BAT) hyperactivation. They perform, in routine settings, a FDG PET-CT scan.
- Trial name
- MICROBAT (NCT04605848)
- Testing
- Infrared themrography
- Where
- France
- Volunteers
- 7 people
- Sponsor
- University of Avignon
Neuroendocrine Tumors
RAD001 and Erlotinib in Patients With Neuroendocrine Tumors
The purpose of this study is to test how safe and effective the combination of RAD001 and erlotinib is in patients with neuroendocrine tumors.
- Trial name
- NCT00843531
- Testing
- RAD001, erlotinib
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of California, San Francisco
Neuroblastoma, Childhood Metastatic Pheochromocytoma
131-I-MIBG Therapy for Refractory Neuroblastoma, Expanded Access Protocol
Metaiodobenzylguanidine (MIBG) is a substance that is taken up by neuroblastoma cells. MIBG is combined with radioactive iodine (131 I) in the laboratory to form a radioactive compound 131 I-MIBG.
- Trial name
- NCT01163383
- Testing
- 131 I-Metaiodobenzylguanidine (131 I-MIBG), 131 I-MIBG
- Where
- United States
- Sponsor
- John Maris
Advanced Pheochromocytoma and Paraganglioma, PCPG
Study of ONC206 (JZP3507) in Advanced Pheochromocytoma and Paraganglioma
This is a two-stage Phase 2 trial evaluating the efficacy and safety of ONC206 in participants with Pheochromocytoma and Paraganglioma (PCPG).
- Trial name
- NCT07282587
- Testing
- ONC206, ONC206: Dose 1, ONC206: Dose 2
- Where
- 9 sites in United States
- Volunteers
- 90 people
- Sponsor
- Jazz Pharmaceuticals
Pheochromocytoma, Paraganglioma
Hereditary Pheochromocytoma Assessment of Tumour Immunologies
In this study, the investigators are examining the role of the immune system in pheochromocytoma and paraganglioma. The investigators aim to examine the differences in the immune system between people who have these tumors with…
- Trial name
- HEPHESTOS (NCT06444607)
- Testing
- Venepuncture
- Where
- Netherlands
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Radboud University Medical Center
Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic
Targeted Alpha-Particle Therapy for Advanced Somatostatin Receptor Type 2 (SSTR2) Positive Tumors
This study is Phase I/IIa First-in-Human Study of [212Pb]VMT-α-NET Targeted Alpha-Particle Therapy for Advanced SSTR2 Positive Tumors
- Conditions
- Neuroendocrine Tumors Unresectable, Neuroendocrine Tumor Metastatic, Gastroenteropancreatic Neuroendocrine Tumor, Bronchial Neuroendocrine Tumor
- Trial name
- NCT05636618
- Testing
- [203Pb]VMT-α-NET, [212Pb]VMT-α-NET
- Where
- 20 sites in United States
- Volunteers
- 300 people
- Sponsor
- Perspective Therapeutics
Pheochromocytoma, Paraganglioma
Specificity of Elevated Plasma EM66 Levels in Pheochromocytoma
Pheochromocytoma or paraganglioma are tumors generating hypertension as a symptom. Different biological tests are currently available to diagnose these tumors.
- Conditions
- Pheochromocytoma, Paraganglioma, Essential Hypertension
- Trial name
- PHEO (NCT01022515)
- Testing
- plasma EM66 & CgA levels assessment, usual follow up with regular EM66 & Cga levels assessment
- Where
- 8 sites in France
- Volunteers
- 60 people
- Sponsor
- University Hospital, Rouen
Thyroid Cancer, Medullary, Carcinoid Tumor
18F-FDOPA PET in Neuroendocrine Tumours
Neuroendocrine tumours (NETs) are a group of neoplasms generally arising from the gastroenteropancreatic tract. They are usually slow growing, have low malignant potential, and often go unnoticed until they become metastatic.
- Conditions
- Thyroid Cancer, Medullary, Carcinoid Tumor, Pheochromocytoma, Paraganglioma
- Trial name
- NCT02431715
- Testing
- [18 F]-6-L-fluorodihydroxyphenylalanine (18F-FDOPA)
- Where
- Canada
- Sponsor
- British Columbia Cancer Agency
Neuroendocrine Carcinomas, Neuroendocrine Tumors
A First-in-Human Phase I Trial With Antibody Drug Conjugate ADCT-701 in Neuroendocrine Tumors, Carcinomas and Malignant Peripheral Nerve Sheath Tumors
Background: Neuroendocrine neoplasms (NENs) are rare cancers in the gastrointestinal tract, pancreas, lungs, adrenal glands, and other areas of the body.
- Conditions
- Neuroendocrine Carcinomas, Neuroendocrine Tumors, Carcinoma, Neuroendocrine, Carcinoma, Adrenocortical
- Trial name
- NCT06041516
- Testing
- ADCT-701
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- National Cancer Institute (NCI)
Neuroendocrine Tumors
Safety and Efficacy Study of In-111 Pentetreotide to Treat Neuroendocrine Tumors
The purpose of this study is to determine if High-dose 111In-Pentetreotide known as NeuroendoMedix®, is an effective treatment for Neuroendocrine Tumors.
- Trial name
- NCT00442533
- Testing
- Indium-111 pentetreotide
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Radio Isotope Therapy of America
Cushing Syndrome, Aldosteronism
China Adrenal Disease Registry
Epidemiologic studies have revealed a tremendous increase in the prevalence of adrenal associated disease and related mortality worldwide.
- Conditions
- Cushing Syndrome, Aldosteronism, Hypoadrenalism, Congenital Adrenal Hyperplasia
- Trial name
- CASE (NCT04890444)
- Where
- China
- Volunteers
- 2,000 people
- Sponsor
- Shanghai Jiao Tong University School of Medicine
Pheochromocytoma, Paraganglioma
Study of Axitinib (AG-013736) With Evaluation of the VEGF-pathway in Pheochromocytoma/Paraganglioma
Primary Objective: To determine the response rate (RR) of metastatic or locally advanced pheochromocytoma/paraganglioma to axitinib administered daily. Secondary Objectives: Determine the progression-free survival.
- Trial name
- NCT03839498
- Testing
- Axitinib
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University